Atara Biotherapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2012-01-01

Employees: 225

Market Cap: $33.6M

Website: http://www.atarabio.com

Introduction: Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Clinical Trials

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus

Phase 1

Withdrawn

Conditions: Lupus Nephritis
Systemic Lupus Erythematosus

Interventions: Drug: ATA3219

First Posted Date: 2024-05-28

Last Posted Date: 2025-04-24

Lead Sponsor: Atara Biotherapeutics

Target Recruit Count: 26

Registration Number: NCT06429800

Locations: 🇺🇸
Atara Biotherapeutics, Thousand Oaks, California, United States

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Phase 1

Terminated

Conditions: Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Interventions: Drug: ATA3219

First Posted Date: 2024-02-13

Last Posted Date: 2025-04-24

Lead Sponsor: Atara Biotherapeutics

Target Recruit Count: 1

Registration Number: NCT06256484

Locations: 🇺🇸
AdventHealth Cancer Institute, Orlando, Florida, United States
🇺🇸
Norton Cancer Institute - Saint Matthews, Louisville, Kentucky, United States
🇺🇸
Sidney Kimmel Cancer Center - Jefferson Health, Philadelphia, Pennsylvania, United States

and more 3 locations

A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases

Phase 2

Recruiting

Conditions: Epstein-Barr Virus (EBV)-Associated Diseases
EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD)
EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD)
EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)
EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
Solid Organ Transplant Complications
Lymphoproliferative Disorders
Allogeneic Hematopoietic Cell Transplant
Stem Cell Transplant Complications
EBV+ Sarcomas

Interventions: Biological: Tabelecleucel

First Posted Date: 2020-09-18

Last Posted Date: 2025-05-11

Lead Sponsor: Atara Biotherapeutics

Target Recruit Count: 190

Registration Number: NCT04554914

Locations: 🇺🇸
University of California Los Angeles (UCLA) (Adults and Pediatrics), LOS Angeles, California, United States
🇺🇸
Children's Hospital of Orange County (Pediatrics [up to 25 years old]), Orange, California, United States
🇺🇸
Lucile Packard Children's Hospital Stanford (Pediatrics only), Palo Alto, California, United States

and more 37 locations

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Phase 1

Terminated

Conditions: Epstein-Barr Viraemia
Nasopharyngeal Neoplasms
Epstein-Barr Virus Infections
Nasopharyngeal Carcinoma
Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Interventions: Biological: Tabelecleucel
Biological: Pembrolizumab

First Posted Date: 2018-12-07

Last Posted Date: 2024-11-14

Lead Sponsor: Atara Biotherapeutics

Target Recruit Count: 12

Registration Number: NCT03769467

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Stanford Hospital and Clinics, Palo Alto, California, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 4 locations

Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis

Phase 1

Terminated

Conditions: Primary Progressive Multiple Sclerosis
Secondary Progressive Multiple Sclerosis

Interventions: Biological: ATA188
Drug: Placebo

First Posted Date: 2017-09-14

Last Posted Date: 2024-02-23

Lead Sponsor: Atara Biotherapeutics

Target Recruit Count: 134

Registration Number: NCT03283826

Locations: 🇺🇸
University of California, San Diego, La Jolla, California, United States
🇺🇸
Kaiser Permanente MS Clinic Los Angeles, Los Angeles, California, United States
🇺🇸
Stanford University, Palo Alto, California, United States

and more 28 locations

Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease

Conditions: CMV Disease
CMV Viremia

First Posted Date: 2017-01-05

Last Posted Date: 2019-04-08

Lead Sponsor: Atara Biotherapeutics

Registration Number: NCT03010332

Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

Conditions: Epstein-Barr Virus (EBV) Infections
Lymphoproliferative Disorders
EBV+ Associated Lymphoma
EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
Epstein-Barr Viremia
Lymphoma, AIDS-related
Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Primary Immunodeficiency (PID)
Leiomyosarcoma (LMS)
Nasopharyngeal Carcinoma (NPC)
Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Acquired Immunodeficiency (AID)

First Posted Date: 2016-07-04

Last Posted Date: 2023-06-15

Lead Sponsor: Atara Biotherapeutics

Registration Number: NCT02822495

Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

Phase 2

Completed

Conditions: EBV-induced Lymphomas
EBV-associated Malignancies
Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma

Interventions: Biological: EBV-specific T cells (EBV-CTLs)

First Posted Date: 2011-12-23

Last Posted Date: 2022-10-21

Lead Sponsor: Atara Biotherapeutics

Target Recruit Count: 87

Registration Number: NCT01498484

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

Phase 1

Completed

Conditions: EBV-induced Lymphomas
EBV-associated Malignancies
Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma

Interventions: Biological: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)

First Posted Date: 2003-01-27

Last Posted Date: 2023-02-13

Lead Sponsor: Atara Biotherapeutics

Target Recruit Count: 58

Registration Number: NCT00002663

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

AI-Powered Research

Premium Access

Atara Biotherapeutics

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis

Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease

Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies